Segmentation of dynamic contrast enhanced magnetic resonance imaging data. - Wikidata - wikimedia - TriplyDB

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

http://www.wikidata.org/entity/Q31165580

about

A criterion for the reliable use of MRI-only radiotherapy.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Subcutaneous tumor volume measurement in the awake, manually restrained mouse using MRI.Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.Biology-guided adaptive radiation therapy - presence or future?Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer.Diffusion-weighted magnetic resonance imaging during radiotherapy of locally advanced cervical cancer--treatment response assessment using different segmentation methods.

P2860

Q37539517-AB054C25-9E17-4DDB-8ED3-31A5D334FCEB Q38168371-B0874E79-1A93-46E2-B0FA-E810B6F2D162 Q39268754-43118156-75D6-42D0-86A3-6D32472E2C2A Q39657204-AB8BB5E0-C190-470C-9536-E598459A1E0D Q42910927-1112A916-0FB2-4081-BABD-4005364BFC50 Q47111454-FA32EE5B-E759-43FA-96FA-E91B3EC246C6 Q51831342-31195BEE-ACFD-4AC7-A317-8D3FDD4FF835

P2860

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

http://www.wikidata.org/entity/Q31165580

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

@ast

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

@en

type

label

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

@ast

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

@en

prefLabel

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

@ast

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

@en

P1433

Q31165580-27BF2418-1CEF-4983-BED0-F7296C865DAE

P1476

Q31165580-D443631D-0F67-4D0E-A4C0-E5F59E0A416D

P2093

Q31165580-B435F901-CFC0-4DC4-9EAD-A36035BDFE13

Q31165580-FFE54570-1DA5-4FCD-B3B7-0C6AC6B05870

P2860

Q31165580-15D51115-88A7-4C4D-B211-BB182E4648DA

Q31165580-1A7BD2A5-519D-4D14-9179-BFEF684F25B6

Q31165580-23D37440-31B3-42E4-98DD-BEB2438AF7DB

Q31165580-26C3909D-F0FE-4B97-8A1F-38999C9B0FF5

Q31165580-3120238F-14E5-472D-BDC8-5B3864201733

Q31165580-35EE07F6-0A49-44B9-8893-29AD9BAA7C9C

Q31165580-3AE0B8D1-0D19-467E-B3D4-8126B0A447C8

Q31165580-3D6C9BE6-7D24-4F37-902A-B2D93DFB9C23

Q31165580-4A2B190C-CF91-4FE8-983D-2B5CCE5A3ECE

Q31165580-4B9D055C-DE2E-453E-9B68-8E77B2AA15AD

P304

Q31165580-D966DCF7-2688-4417-8253-838E31250E51

P31

Q31165580-7BC5CC6E-46B7-4BDC-8CBF-1C0F46A1E2C1

P356

Q31165580-654DA4FC-9C98-4A7C-878A-90D8762CF3B3

P433

Q31165580-2E4138AA-CCFE-4E4A-9657-1B1ABC5E454D

P478

Q31165580-B4F81B90-5ADB-460A-B023-224D65EAE843

P50

Q31165580-171D5A60-0750-4366-AD32-0C0AE6063597

Q31165580-DDF42833-F34C-4635-8BA0-F75FA4B92C4C

Q31165580-EBCAB18F-458C-4316-833F-144017CA626B

Q31165580-EE17D70E-53C7-47FC-B44E-7B9D693E43E7

P577

Q31165580-4B9FE0E3-DE77-4276-8DD9-F38E76006CC4

P5875

Q31165580-069B1E5A-FB21-426E-96A7-9D948E3C4F02

P698

Q31165580-64971B24-0AC7-4B57-A1BA-BE5FF66E63FA

P356

02841860802277489

P1433

Acta Oncologica

P1476

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

@en

P2093

Ross J Maxwell

http://www.w3.org/2001/XMLSchema#string

Thomas Nielsen

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Perfusion MR imaging of extracranial tumor angiogenesis.

Characterizing the tumor response to treatment with combretastatin A4 phosphate.

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy.

Monitoring the treatment efficacy of the vascular disrupting agent CA4P.

Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.

Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.

P304

1265-1270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/02841860802277489

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Leif Østergaard

Hans Stødkilde-Jørgensen

Michael R. Horsman

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51432251

http://www.w3.org/2001/XMLSchema#string

P698

18661437

http://www.w3.org/2001/XMLSchema#string